AMY SIMPSON-WAID: Open Payments
NPI 1710209184 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,584 in 92 payments from 20 companies in 2025. Trend: 2023 $1,578 · 2024 $1,311 · 2025 $1,584
Food & beverage: $1,584
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $169 |
| Amgen Inc. | 10 | $162 |
| Lilly USA, LLC | 10 | $150 |
| GlaxoSmithKline, LLC. | 13 | $141 |
| Sumitomo Pharma America, Inc. | 7 | $122 |
| Abbott Laboratories | 6 | $105 |
| Novo Nordisk Inc | 5 | $98 |
| Corcept Therapeutics | 4 | $76 |
| Merck Sharp & Dohme LLC | 3 | $66 |
Products named: CAPLYTA, MOUNJARO, GEMTESA, EVENITY, FREESTYLE LIBRE, FARXIGA, Ozempic, SHINGRIX.
Industry payments across MS — which companies pay providers there.
